Therefore, the observation of broader hemizygous mutations that increase the overall frequency of PTEN gene alterations in ER+/HER2- BC biopsies with PIK3CA activating mutations across different clinical datasets is intriguing. The gene discussed is PTEN; the disease is breast cancer.